{"id":7176,"date":"2025-04-26T17:03:26","date_gmt":"2025-04-26T22:03:26","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=6023"},"modified":"2025-07-13T15:09:30","modified_gmt":"2025-07-13T20:09:30","slug":"nanoscope-participation-at-eyecelerator-and-arvo-2025","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/ja\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/","title":{"rendered":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u3001Eyecelerator\u00ae\u304a\u3088\u3073ARVO 2025\u5e74\u6b21\u7dcf\u4f1a\u3078\u306e\u53c2\u52a0\u3092\u767a\u8868"},"content":{"rendered":"<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<h3 class=\"prntac\" style=\"text-align: center;\"><em>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u793e\u306e\u5149\u907a\u4f1d\u5b66\u7642\u6cd5\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306e\u6709\u52b9\u6027\u3001\u8010\u4e45\u6027\u3001\u5b89\u5168\u6027\u3092\u5f37\u8abf\u3059\u308b\u30d7\u30ec\u30bc\u30f3\u30c6\u30fc\u30b7\u30e7\u30f3<\/em><\/h3>\n<\/div>\n<div class=\"col-sm-4 col-xs-12 col-vcenter\">\n<div class=\"image logo logo-wrapper\" data-src=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=publish\" data-asset-type=\"photo\" data-asset-label=\"Logo\" data-download-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg\" data-tweet-text=\"Nanoscope Therapeutics Logo (PRNewsfoto\/Nanoscope Therapeutics)\" data-pinterest-text=\"Nanoscope Therapeutics Logo (PRNewsfoto\/Nanoscope Therapeutics)\" data-linkedin-text=\"Nanoscope Therapeutics Logo (PRNewsfoto\/Nanoscope Therapeutics)\" data-facebook-share-text=\"Nanoscope Therapeutics Logo (PRNewsfoto\/Nanoscope Therapeutics)\" data-twitter-share-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=twitter\" data-facebook-share-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=facebook\" data-pinterest-share-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=publish\" data-linkedin-share-url=\"https:\/\/mma.prnewswire.com\/media\/1333752\/Nanoscope_Therapeutics_Logo.jpg?p=linkedin\">\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">\u30c0\u30e9\u30b9<\/span><\/span>,\u00a0<span class=\"legendSpanClass\"><span class=\"xn-chron\">2025\u5e744\u670825\u65e5<\/span><\/span>\u00a0 \u2014 <a href=\"http:\/\/nanostherapeutics.com\/ja\/\" target=\"_blank\" rel=\"nofollow noopener\">\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u682a\u5f0f\u4f1a\u793e<\/a>, \u7db2\u819c\u5909\u6027\u75be\u60a3\u306b\u5bfe\u3059\u308b\u65b0\u898f\u907a\u4f1d\u5b50\u6cbb\u7642\u306e\u958b\u767a\u3068\u5546\u696d\u5316\u3092\u901a\u3058\u3066\u3001\u73fe\u5b9f\u4e16\u754c\u3067\u76f2\u76ee\u306e\u60a3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u3053\u3068\u306b\u5c3d\u529b\u3059\u308b\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u4f01\u696d\u3067\u3042\u308b \u306f\u672c\u65e5\u3001\u00a0<a href=\"https:\/\/www.eyecelerator.com\/\" target=\"_blank\" rel=\"nofollow noopener\">\u30a2\u30a4\u30bb\u30e9\u30ec\u30fc\u30bf<\/a>\u00a0\u305d\u3057\u3066\u00a0<a href=\"https:\/\/www.arvo.org\/annual-meeting\/\" target=\"_blank\" rel=\"nofollow noopener\">\u773c\u79d1\u5b66\u7814\u7a76\u30fb\u8996\u899a\u5354\u4f1a\uff08ARVO\uff092025<\/a>\u00a0\u5e74\u6b21\u7dcf\u4f1a\u3002\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u306e\u30d7\u30ec\u30bc\u30f3\u30c6\u30fc\u30b7\u30e7\u30f3\u306f\u3001\u540c\u793e\u306e\u88fd\u54c1\u306b\u3088\u308b\u6cbb\u7642\u5f8c126\u9031\u9593\u306e\u7d50\u679c\u3092\u4e2d\u5fc3\u306b\u5c55\u958b\u3055\u308c\u308b\u4e88\u5b9a\u3067\u3059\u3002\u00a0<a href=\"https:\/\/nanostherapeutics.com\/ja\/technology-2\/\" target=\"_blank\" rel=\"nofollow noopener\">MCO-010\u5149\u907a\u4f1d\u5b66\u7642\u6cd5<\/a>\u00a0\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\u306b\u5bfe\u3059\u308b\u6700\u521d\u3067\u552f\u4e00\u306e\u6cbb\u7642\u6cd5\u00a0<a href=\"https:\/\/www.cell.com\/molecular-therapy-family\/molecular-therapy\/fulltext\/S1525-0016(25)00205-9\" target=\"_blank\" rel=\"nofollow noopener\">\u9032\u884c\u6027\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u60a3\u8005\u306e\u8996\u529b\u56de\u5fa9\u306b\u52b9\u679c\u304c\u3042\u308b\u3053\u3068\u304c\u793a\u3055\u308c\u3066\u3044\u308b\u3002<\/a>\u00a01\u56de\u9650\u308a\u306e\u6a19\u6e96\u7684\u306a\u785d\u5b50\u4f53\u5185\u6ce8\u5c04\u306b\u3088\u3063\u3066\u6295\u4e0e\u3055\u308c\u308b\u3002.<\/p>\n<p>\u201c\u300cEyecelerator\u3068ARVO\u306e\u5e74\u6b21\u7dcf\u4f1a\u306e\u4e21\u65b9\u306b\u3053\u308c\u307b\u3069\u5927\u304d\u306a\u5b58\u5728\u611f\u3092\u793a\u3059\u3053\u3068\u304c\u3067\u304d\u3001\u5927\u5909\u5b09\u3057\u304f\u601d\u3044\u307e\u3059\u3002\u307e\u305f\u3001\u5f53\u793e\u306e\u591a\u7279\u6027\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u7642\u6cd5\u3067\u6cbb\u7642\u3055\u308c\u305f\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u60a3\u8005\u306b\u898b\u3089\u308c\u308b\u80af\u5b9a\u7684\u306a\u6cbb\u7642\u52b9\u679c\u306b\u3064\u3044\u3066\u3001\u3055\u3089\u306b\u8a73\u3057\u304f\u304a\u4f1d\u3048\u3067\u304d\u308b\u3053\u3068\u3092\u697d\u3057\u307f\u306b\u3057\u3066\u3044\u307e\u3059\u300d\u3068\u3001\u535a\u58eb\u306f\u8ff0\u3079\u3066\u3044\u307e\u3059\u3002.\u00a0<span class=\"xn-person\">\u30b5\u30de\u30ec\u30f3\u30c9\u30e9\u30fb\u30e2\u30cf\u30f3\u30c6\u30a3<\/span>, \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u793e\u306e\u5171\u540c\u5275\u696d\u8005\u517c\u793e\u9577\u306f\u6b21\u306e\u3088\u3046\u306b\u8ff0\u3079\u3066\u3044\u307e\u3059\u3002\u300c\u8907\u6570\u5e74\u306b\u308f\u305f\u308b\u52b9\u679c\u306f\u3001\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\u306b\u3088\u308b\u4e0d\u53ef\u9006\u7684\u3067\u9032\u884c\u6027\u306e\u8996\u529b\u4f4e\u4e0b\u306b\u5bfe\u3057\u3001\u4e00\u5ea6\u306e\u6301\u7d9a\u7684\u306a\u6cbb\u7642\u9078\u629e\u80a2\u3092\u6c42\u3081\u308b\u60a3\u8005\u306b\u3068\u3063\u3066\u975e\u5e38\u306b\u610f\u7fa9\u6df1\u304f\u3001MCO-010\u304c\u6a19\u6e96\u6cbb\u7642\u3092\u518d\u5b9a\u7fa9\u3059\u308b\u53ef\u80fd\u6027\u3092\u79d8\u3081\u3066\u3044\u308b\u3053\u3068\u3092\u793a\u3057\u3066\u3044\u307e\u3059\u3002MCO-010\u306e\u5546\u696d\u5316\u3001\u7279\u306b\u751f\u7269\u88fd\u5264\u627f\u8a8d\u7533\u8acb\uff08BLA\uff09\u306e\u6e96\u5099\u3092\u9032\u3081\u3066\u3044\u308b\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u793e\u306b\u3068\u3063\u3066\u3001\u4eca\u306f\u975e\u5e38\u306b\u30a8\u30ad\u30b5\u30a4\u30c6\u30a3\u30f3\u30b0\u306a\u6642\u671f\u3067\u3059\u3002\u300d\u201c<\/p>\n<p>\u30d7\u30ec\u30bc\u30f3\u30c6\u30fc\u30b7\u30e7\u30f3\u306e\u8a73\u7d30\u306f\u4ee5\u4e0b\u306e\u3068\u304a\u308a\u3067\u3059\u3002<\/p>\n<p><b><a href=\"https:\/\/www.eyecelerator.com\/\" target=\"_blank\" rel=\"nofollow noopener\">\u30a2\u30a4\u30bb\u30e9\u30ec\u30fc\u30bf\u00a0<\/a><\/b><br class=\"dnr\" \/><span class=\"xn-chron\">5\u67082\u65e5\uff08\u91d1\uff09<\/span><sup>nd<\/sup>, 2025<br class=\"dnr\" \/>\u30b0\u30e9\u30f3\u30c9\u00a0<span class=\"xn-person\">\u30cf\u30a4\u30a2\u30c3\u30c8\u30fb\u30c7\u30a3\u30a2\u30d0\u30ec\u30fc<\/span>,\u00a0<span class=\"xn-location\">\u30e6\u30bf\u5dde\u30d1\u30fc\u30af\u30b7\u30c6\u30a3<\/span><\/p>\n<p>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u306e\u53c2\u52a0\uff1a<\/p>\n<ul type=\"disc\">\n<li><b>\u5348\u5f8c12\u664230\u5206\uff5e\u5348\u5f8c1\u664230\u5206\uff08\u5c71\u5cb3\u90e8\u6a19\u6e96\u6642\uff09\u00a0<\/b>\u2013 \u30d1\u30cd\u30eb \u2013 \u79c1\u306f\u89e3\u653e\u3055\u308c\u308b\u3067\u3057\u3087\u3046: \u7dd1\u5185\u969c\u3068\u7db2\u819c\u306b\u5bfe\u3059\u308b\u65b0\u3057\u3044\u85ac\u7269\u9001\u9054\u30a2\u30d7\u30ed\u30fc\u30c1 \u2013 \u535a\u58eb\u3002.\u00a0<span class=\"xn-person\">\u30b5\u30e0\u30fb\u30d0\u30ed\u30f3<\/span>, \u6700\u9ad8\u533b\u7642\u8cac\u4efb\u8005<br class=\"dnr\" \/><br class=\"dnr\" \/><\/li>\n<li><b>\u5348\u5f8c1\u664259\u5206\uff5e\u5348\u5f8c2\u664204\u5206\uff08\u5c71\u5cb3\u90e8\u6a19\u6e96\u6642\uff09\u3001\u30b9\u30c8\u30ed\u30d9\u30ea\u30fc\u30dc\u30fc\u30eb\u30eb\u30fc\u30e0\u00a0<\/b>\u2013 \u30d7\u30ec\u30bc\u30f3\u30c6\u30a3\u30f3\u30b0\u30ab\u30f3\u30d1\u30cb\u30fc\u30b7\u30e7\u30fc\u30b1\u30fc\u30b9\uff1a\u7db2\u819c\uff1a\u907a\u4f1d\u5b50\u6cbb\u7642\u3068\u65b0\u3057\u3044\u4f5c\u7528\u6a5f\u5e8f \u2013 Dr.\u00a0<span class=\"xn-person\">\u30b8\u30e3\u30ec\u30c3\u30c9\u30fb\u30b9\u30c6\u30a3\u30fc\u30d6\u30f3\u30b9<\/span>, \u6226\u7565\u30fb\u4e8b\u696d\u958b\u767a\u62c5\u5f53\u526f\u793e\u9577<br class=\"dnr\" \/><br class=\"dnr\" \/><\/li>\n<li><b>3:30 \u2013\u00a0<span class=\"xn-chron\">\u5348\u5f8c4\u664215\u5206<\/span><\/b>\u00a0<b>MDT<\/b>\u00a0\u2013 \u30d1\u30cd\u30eb \u2013 \u884c\u304d\u5148\u304c\u308f\u304b\u3089\u306a\u3044\uff1a\u307e\u3059\u307e\u3059\u8907\u96d1\u5316\u3059\u308b\u898f\u5236\u7d4c\u8def\u3092\u30ca\u30d3\u30b2\u30fc\u30c8\u3059\u308b\u305f\u3081\u306e\u30ac\u30a4\u30c0\u30f3\u30b9 \u2013 \u535a\u58eb\u3002.\u00a0<span class=\"xn-person\">\u30b5\u30e0\u30fb\u30d0\u30ed\u30f3<\/span><\/li>\n<\/ul>\n<p><b><a href=\"https:\/\/www.arvo.org\/annual-meeting\/\" target=\"_blank\" rel=\"nofollow noopener\">ARVO\uff08\u8996\u899a\u30fb\u773c\u79d1\u5b66\u7814\u7a76\u5354\u4f1a\uff09<\/a><br class=\"dnr\" \/><\/b><span class=\"xn-chron\">5\u67084\u65e5\uff08\u65e5\uff09<\/span><sup>\u756a\u76ee<\/sup>\u00a0\u306b\u00a0<span class=\"xn-chron\">5\u67088\u65e5\uff08\u6728\uff09<\/span><sup>\u756a\u76ee<\/sup>, 2025<br class=\"dnr\" \/>\u30bd\u30eb\u30c8\u30d1\u30ec\u30b9\u30b3\u30f3\u30d9\u30f3\u30b7\u30e7\u30f3\u30bb\u30f3\u30bf\u30fc,\u00a0<span class=\"xn-location\">\u30e6\u30bf\u5dde\u30bd\u30eb\u30c8\u30ec\u30a4\u30af\u30b7\u30c6\u30a3<\/span><\/p>\n<p>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u306e\u30d7\u30ec\u30bc\u30f3\u30c6\u30fc\u30b7\u30e7\u30f3\uff1a<\/p>\n<ul type=\"disc\">\n<li><b><span class=\"xn-chron\">5\u67084\u65e5\uff08\u65e5\uff09<\/span><sup>\u756a\u76ee<\/sup>, 1:30 \u2013\u00a0<span class=\"xn-chron\">\u5348\u5f8c1\u664245\u5206\uff08\u5c71\u5cb3\u90e8\u6a19\u6e96\u6642\uff09<\/span>; \u30dc\u30fc\u30eb\u30eb\u30fc\u30e0G\u00a0<\/b>- MS\u3002.\u00a0<span class=\"xn-person\">\u30eb\u30bb\u30ed\u30fb\u30ac\u30eb\u30b7\u30a2<\/span>\u00a0\u767a\u8868\u5185\u5bb9\uff1a\u300c\u591a\u6a5f\u80fd\u30aa\u30d7\u30b7\u30f3\u907a\u4f1d\u5b50\u6cbb\u7642\u306f\u3001\u5730\u56f3\u72b6\u840e\u7e2e\u75c7\u306e\u975e\u30d2\u30c8\u970a\u9577\u985e\u30e2\u30c7\u30eb\u306b\u304a\u3044\u3066\u7db2\u819c\u5909\u6027\u3092\u8efd\u6e1b\u3057\u3001\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u300d\u201c<br class=\"dnr\" \/><br class=\"dnr\" \/><\/li>\n<li><b><span class=\"xn-chron\">5\u67086\u65e5\uff08\u706b\uff09<\/span><sup>\u756a\u76ee<\/sup>, 9:15 \u2013\u00a0<span class=\"xn-chron\">\u5348\u524d9\u664230\u5206\uff08\u5c71\u5cb3\u90e8\u6a19\u6e96\u6642\uff09<\/span>; \u30dc\u30fc\u30eb\u30eb\u30fc\u30e0B\u00a0<\/b>\u2013 \u30b9\u30ea\u30cb\u30f4\u30a1\u30b9\u30fb\u30b5\u30c3\u30c0\u535a\u58eb\u306b\u3088\u308b\u767a\u8868 \u2013 \u300c\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\u306b\u5bfe\u3059\u308b\u907a\u4f1d\u5b50\u5909\u7570\u975e\u4f9d\u5b58\u578b\u5149\u907a\u4f1d\u5b66\u7684\u6cbb\u7642\u6cd5MCO-010\u6295\u4e0e\u5f8c\u306e126\u9031\u9593\u306e\u8996\u529b\u8ee2\u5e30\u300d\u201c<br class=\"dnr\" \/><br class=\"dnr\" \/><\/li>\n<li><b><span class=\"xn-chron\">5\u67088\u65e5\uff08\u6728\uff09<\/span><sup>\u756a\u76ee<\/sup>, 2:45 \u2013\u00a0<span class=\"xn-chron\">\u5348\u5f8c3\u6642\uff08\u5c71\u5cb3\u90e8\u6a19\u6e96\u6642\uff09<\/span>; \u30dc\u30fc\u30eb\u30eb\u30fc\u30e0F\u00a0<\/b>\u2013 \u535a\u58eb.\u00a0<span class=\"xn-person\">\u30ca\u30b8\u30fb\u30b7\u30e3\u30ea\u30d5<\/span>\u00a0\u767a\u8868\u5185\u5bb9\uff1a\u300c\u30a2\u30d5\u30ea\u30ab\u30df\u30c9\u30ea\u30b6\u30eb\u7db2\u819c\u306b\u304a\u3051\u308b\u591a\u7279\u6027\u30aa\u30d7\u30b7\u30f3\u30d7\u30e9\u30b9\u30df\u30c9\u306e\u753b\u50cf\u8a98\u5c0e\u30ec\u30fc\u30b6\u30fc\u30d9\u30fc\u30b9\u975e\u30a6\u30a4\u30eb\u30b9\u6a19\u7684\u9001\u9054\u306e\u5b89\u5168\u6027\u3068\u6709\u52b9\u6027\u300d\u201c<\/li>\n<\/ul>\n<p>ARVO\u4f1a\u8b70\u306e\u671f\u9593\u4e2d\u3001Nanoscope\u306e\u30c1\u30fc\u30e0\u30e1\u30f3\u30d0\u30fc\u306f\u30d6\u30fc\u30b91337\u306b\u3066\u5bfe\u5fdc\u3044\u305f\u3057\u307e\u3059\u3002.<\/p>\n<p><b>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u306b\u3064\u3044\u3066<br class=\"dnr\" \/><\/b>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u306f\u3001\u73fe\u5728\u6cbb\u7642\u6cd5\u304c\u306a\u3044\u7db2\u819c\u5909\u6027\u75be\u60a3\u3067\u5931\u660e\u3057\u305f\u4f55\u767e\u4e07\u4eba\u3082\u306e\u60a3\u8005\u306e\u305f\u3081\u306b\u3001\u5909\u7570\u306b\u4f9d\u5b58\u3057\u306a\u3044\u8996\u529b\u56de\u5fa9\u30aa\u30d7\u30c8\u30b8\u30a7\u30cd\u30c6\u30a3\u30c3\u30af\u7642\u6cd5\u3092\u958b\u767a\u3057\u3066\u3044\u307e\u3059\u3002\u7db2\u819c\u5909\u6027\u75be\u60a3\u306b\u5bfe\u3059\u308bRESTORE\u30d5\u30a7\u30fc\u30ba2b\u591a\u65bd\u8a2d\u30e9\u30f3\u30c0\u30e0\u5316\u4e8c\u91cd\u76f2\u691c\u507d\u5bfe\u7167\u81e8\u5e8a\u8a66\u9a13\u306e\u826f\u597d\u306a\u8a66\u9a13\u7d42\u4e86\u7d50\u679c\u3092\u53d7\u3051\u3066\uff08<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04945772\" target=\"_blank\" rel=\"nofollow noopener\">NCT04945772<\/a>\uff09\u3001\u540c\u793e\u306f\u3001\u00a0<a href=\"https:\/\/nanostherapeutics.com\/ja\/2024\/10\/10\/nanoscope-announces-plans-to-submit-bla-for-mco-010-to-treat-retinitis-pigmentosa\/\" target=\"_blank\" rel=\"nofollow noopener\">RP\u6cbb\u7642\u85acMCO-010\u306eBLA\u7533\u8acb<\/a>\u00a0\u540c\u793e\u306f\u3001\u30b9\u30bf\u30fc\u30ac\u30eb\u30c8\u75c5\u60a3\u8005\u3092\u5bfe\u8c61\u3068\u3057\u305fMCO-010\u7642\u6cd5\u306e\u7b2c2\u76f8STARLIGHT\u8a66\u9a13\u3092\u5b8c\u4e86\u3057\u305f\uff08<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05417126\" target=\"_blank\" rel=\"nofollow noopener\">NCT05417126<\/a>\uff09\u3092\u958b\u59cb\u3057\u3001\u00a0<a href=\"https:\/\/nanostherapeutics.com\/ja\/2024\/09\/12\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-u-s-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration\/\" target=\"_blank\" rel=\"nofollow noopener\">\u30d5\u30a7\u30fc\u30ba3\u767b\u9332\u8a66\u9a13<\/a>, 2025\u5e74\u306b\u3082\u3001MCO-010\u306f\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\u3068\u30b9\u30bf\u30fc\u30ac\u30eb\u30c8\u75c5\u306e\u4e21\u65b9\u3067FDA\u306e\u30d5\u30a1\u30b9\u30c8\u30c8\u30e9\u30c3\u30af\u6307\u5b9a\u3068\u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u6307\u5b9a\u3092\u53d7\u3051\u3066\u3044\u307e\u3059\u3002\u524d\u81e8\u5e8a\u30d7\u30ed\u30b0\u30e9\u30e0\u306b\u306f\u3001\u7db2\u819c\u840e\u7e2e\u75c7\uff08GA\uff09\u5411\u3051\u306eIND\u7533\u8acb\u6e96\u5099\u304c\u6574\u3063\u305f\u975e\u30a6\u30a4\u30eb\u30b9\u6027\u30ec\u30fc\u30b6\u30fc\u9001\u9054\u578bMCO-020\u3001\u304a\u3088\u3073\u30ec\u30fc\u30d0\u30fc\u5148\u5929\u6027\u9ed2\u5185\u969c\u5411\u3051\u306eAAV\u88fd\u5264\uff08IND\u7533\u8acb\u306b\u5411\u3051\u305f\u7814\u7a76\u4e2d\uff09\u304c\u542b\u307e\u308c\u307e\u3059\u3002.<\/p>\n<p><b>\u6295\u8cc7\u5bb6\u9023\u7d61\u5148:<\/b><br class=\"dnr\" \/>\u30a2\u30eb\u30b4\u30c3\u30c8\u30d1\u30fc\u30c8\u30ca\u30fc\u30ba<br class=\"dnr\" \/>212-600-1902<br class=\"dnr\" \/><a href=\"mailto:PR@nanostherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">PR@nanostherapeutics.com<\/a><\/p>\n<p>\u51fa\u5178 \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Presentations to highlight efficacy, durability, and safety of\u00a0Nanoscope\u2019s optogenetic therapy platforms DALLAS,\u00a0April 25, 2025\u00a0 \u2014 Nanoscope Therapeutics Inc., a biotech company committed to restoring vision in blind patients in real-world settings by developing and commercializing novel gene therapies for retinal degenerative diseases, today announced participation at both the\u00a0Eyecelerator\u00a0and\u00a0The Association for Research and Vision in Ophthalmology (ARVO) 2025\u00a0annual meetings. Nanoscope\u2019s presentations will be centered around 126-week outcomes following treatment with its\u00a0MCO-010 optogenetic therapy\u00a0for retinitis pigmentosa (RP), the first and only therapy\u00a0shown to restore vision in advanced RP patients\u00a0via a one-time, standard intravitreal injection. \u201cWe are excited to have such a substantial presence at both the Eyecelerator and ARVO annual meetings and [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":7179,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-7176","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Therapeutics Announces Participation at Eyecelerator\u00ae and ARVO 2025 Annual Meetings - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/ja\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Announces Participation at Eyecelerator\u00ae and ARVO 2025 Annual Meetings - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/ja\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-26T22:03:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-13T20:09:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_LI_MOLECULARTHERAPY_V1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_LI_MOLECULARTHERAPY_V1.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"3\u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/04\\\/26\\\/nanoscope-participation-at-eyecelerator-and-arvo-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/04\\\/26\\\/nanoscope-participation-at-eyecelerator-and-arvo-2025\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics Announces Participation at Eyecelerator\u00ae and ARVO 2025 Annual Meetings\",\"datePublished\":\"2025-04-26T22:03:26+00:00\",\"dateModified\":\"2025-07-13T20:09:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/04\\\/26\\\/nanoscope-participation-at-eyecelerator-and-arvo-2025\\\/\"},\"wordCount\":555,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/04\\\/26\\\/nanoscope-participation-at-eyecelerator-and-arvo-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/NSCOPE_ARVO_LI_2025-.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"ja\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/04\\\/26\\\/nanoscope-participation-at-eyecelerator-and-arvo-2025\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/04\\\/26\\\/nanoscope-participation-at-eyecelerator-and-arvo-2025\\\/\",\"name\":\"Nanoscope Therapeutics Announces Participation at Eyecelerator\u00ae and ARVO 2025 Annual Meetings - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/04\\\/26\\\/nanoscope-participation-at-eyecelerator-and-arvo-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/04\\\/26\\\/nanoscope-participation-at-eyecelerator-and-arvo-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/NSCOPE_ARVO_LI_2025-.jpg\",\"datePublished\":\"2025-04-26T22:03:26+00:00\",\"dateModified\":\"2025-07-13T20:09:30+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/04\\\/26\\\/nanoscope-participation-at-eyecelerator-and-arvo-2025\\\/#breadcrumb\"},\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/04\\\/26\\\/nanoscope-participation-at-eyecelerator-and-arvo-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/04\\\/26\\\/nanoscope-participation-at-eyecelerator-and-arvo-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/NSCOPE_ARVO_LI_2025-.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/NSCOPE_ARVO_LI_2025-.jpg\",\"width\":1000,\"height\":1000},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/04\\\/26\\\/nanoscope-participation-at-eyecelerator-and-arvo-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Announces Participation at Eyecelerator\u00ae and ARVO 2025 Annual Meetings\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ja\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u3001Eyecelerator\u00ae\u304a\u3088\u3073ARVO 2025\u5e74\u6b21\u7dcf\u4f1a\u3078\u306e\u53c2\u52a0\u3092\u767a\u8868 - \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","description":"\u5f53\u793e\u306e\u591a\u6a5f\u80fd\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306f\u3001\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3044\u3066\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u3092\u4f34\u3046\u7db2\u819c\u75be\u60a3\u60a3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u80fd\u529b\u3092\u5b9f\u8a3c\u3057\u305f\u521d\u306e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3059\u3002Nanoscope\u793e\u306f\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u3001\u5e83\u7bc4\u56f2\u306e\u30b9\u30da\u30af\u30c8\u30eb\u3001\u9ad8\u901f\u5fdc\u7b54\u6027\u3001\u8d85\u9ad8\u611f\u5ea6\u3092\u5099\u3048\u305f\u3001\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u6700\u521d\u3067\u552f\u4e00\u306e\u5149\u907a\u4f1d\u5b66\u6280\u8853\u3067\u3042\u308bMCO-010\u3092\u958b\u767a\u3057\u307e\u3057\u305f\u3002.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/ja\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/","og_locale":"ja_JP","og_type":"article","og_title":"Nanoscope Therapeutics Announces Participation at Eyecelerator\u00ae and ARVO 2025 Annual Meetings - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/ja\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2025-04-26T22:03:26+00:00","article_modified_time":"2025-07-13T20:09:30+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_LI_MOLECULARTHERAPY_V1.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_LI_MOLECULARTHERAPY_V1.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"\u57f7\u7b46\u8005":"Nanoscope Therapeutics","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"3\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics Announces Participation at Eyecelerator\u00ae and ARVO 2025 Annual Meetings","datePublished":"2025-04-26T22:03:26+00:00","dateModified":"2025-07-13T20:09:30+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/"},"wordCount":555,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/04\/NSCOPE_ARVO_LI_2025-.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/","url":"https:\/\/nanostherapeutics.com\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u3001Eyecelerator\u00ae\u304a\u3088\u3073ARVO 2025\u5e74\u6b21\u7dcf\u4f1a\u3078\u306e\u53c2\u52a0\u3092\u767a\u8868 - \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/04\/NSCOPE_ARVO_LI_2025-.jpg","datePublished":"2025-04-26T22:03:26+00:00","dateModified":"2025-07-13T20:09:30+00:00","description":"\u5f53\u793e\u306e\u591a\u6a5f\u80fd\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306f\u3001\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3044\u3066\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u3092\u4f34\u3046\u7db2\u819c\u75be\u60a3\u60a3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u80fd\u529b\u3092\u5b9f\u8a3c\u3057\u305f\u521d\u306e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3059\u3002Nanoscope\u793e\u306f\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u3001\u5e83\u7bc4\u56f2\u306e\u30b9\u30da\u30af\u30c8\u30eb\u3001\u9ad8\u901f\u5fdc\u7b54\u6027\u3001\u8d85\u9ad8\u611f\u5ea6\u3092\u5099\u3048\u305f\u3001\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u6700\u521d\u3067\u552f\u4e00\u306e\u5149\u907a\u4f1d\u5b66\u6280\u8853\u3067\u3042\u308bMCO-010\u3092\u958b\u767a\u3057\u307e\u3057\u305f\u3002.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/nanostherapeutics.com\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/04\/NSCOPE_ARVO_LI_2025-.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/04\/NSCOPE_ARVO_LI_2025-.jpg","width":1000,"height":1000},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2025\/04\/26\/nanoscope-participation-at-eyecelerator-and-arvo-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Announces Participation at Eyecelerator\u00ae and ARVO 2025 Annual Meetings"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","description":"\u5e0c\u671b\u306e\u5149\u3092\u53d6\u308a\u623b\u3059","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/7176","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/comments?post=7176"}],"version-history":[{"count":3,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/7176\/revisions"}],"predecessor-version":[{"id":7213,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/7176\/revisions\/7213"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/media\/7179"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/media?parent=7176"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/categories?post=7176"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/tags?post=7176"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}